US MoCRA vs EU Cosmetics Regulation: Key Differences Every Brand Should Know (2026)

If your brand sells skincare or cosmetics in both the United States and Europe, you're working under two very different rulebooks. The US framework is built around the Modernization of Cosmetics Regulation Act (MoCRA), while the European Union operates under Regulation (EC) No 1223/2009, generally referred to as the EU Cosmetics Regulation.

Both frameworks share a common goal: making sure cosmetic products are safe, traceable, and properly documented before they reach consumers. But the way each region gets there looks quite different. Understanding those differences early can save a brand owner months of delay, unexpected costs, or a product held at customs.

Why This Comparison Matters for Brand Owners

Many private label and indie beauty brands assume that once a product is compliant in one market, it's compliant everywhere. That assumption tends to cause problems. A formulation approved for US sale under MoCRA can still fail EU notification requirements if the safety assessment, ingredient documentation, or labeling doesn't match what Regulation 1223/2009 expects.

For brand owners planning international expansion, knowing where the two systems overlap and where they diverge is a practical planning tool, not just a compliance checkbox.

MoCRA: What US Cosmetic Brands Must Prepare For

MoCRA, signed into law in December 2022, replaced the FDA's old voluntary registration system with a mandatory one. The core obligations include:

• Facility registration (Form FDA 5066): Manufacturers and processors of cosmetics distributed in the US must register each facility with the FDA. Registration requires an FDA Establishment Identifier (FEI) number and must be renewed every two years from the initial registration date.
• Product listing (Form FDA 5067): The Responsible Person, meaning the entity named on the product label, must list each marketed product annually, including its ingredients.
• Safety substantiation: The Responsible Person must maintain records supporting that a product is safe for its intended use.
• Adverse event reporting: Serious adverse events must be reported to the FDA, and records must be kept for a defined retention period.
• Labeling requirements: Labels must include a domestic address, phone number, or electronic contact through which consumers can report adverse events.

Facility registration and product listing became enforceable on July 1, 2024, and many facilities are now going through their first biennial renewal cycle. Some provisions, including mandatory cosmetic GMP regulations and fragrance allergen disclosure rules, are still in the rulemaking stage and haven't been finalized yet. Brands should treat these as developing requirements to monitor rather than settled rules.

EU Cosmetics Regulation: What It Requires Instead

The EU system, Regulation (EC) No 1223/2009, has been in force since 2013 and applies uniformly across all EU member states without needing separate national laws. Its structure centers on documentation completed before a product ever reaches the shelf, rather than registration renewed afterward.

Key requirements include:

• A Responsible Person established in the EU: Every cosmetic product sold in the EU market needs a named Responsible Person based within the EU, even if the brand itself is located elsewhere.
• Cosmetic Product Safety Report (CPSR): A safety assessment covering the product's technical data and an expert evaluation must be completed before the product can be sold.
• Product Information File (PIF): A comprehensive technical dossier, including the CPSR, must be maintained and kept available to authorities for ten years after the product's last batch is placed on the market.
• CPNP notification: Before a product is first sold anywhere in the EU, it must be notified through the Cosmetic Products Notification Portal, providing details like product category, ingredient composition, and presence of nanomaterials.
• Ingredient annexes: Substances are governed by regularly updated Annexes (II through VI), which restrict or ban specific ingredients. These are amended multiple times a year, so ongoing monitoring is part of compliance, not a one-time check.

Unlike MoCRA's post-registration renewal model, EU notification has no grace period. A product found on the market without CPNP notification can be withdrawn immediately.

Side-by-Side: Where the Systems Diverge

• Timing: MoCRA allows facility registration alongside ongoing operations, with defined renewal cycles. The EU requires safety documentation and notification to be complete before the first sale.
• Who is accountable: Both systems use a "Responsible Person" concept, but MoCRA splits responsibility between the facility (registration) and the label owner (product listing), while the EU places most obligations on a single EU-based Responsible Person.
• Documentation style: MoCRA relies on structured product listing (SPL format) submitted electronically. The EU relies on the PIF, a detailed technical file that stays with the Responsible Person rather than being fully submitted to a central authority.
• Ingredient oversight: The EU's Annexes are updated frequently and can affect currently marketed products. MoCRA does not yet have a finalized ingredient-restriction mechanism as far-reaching as the EU Annexes, though FDA authority over ingredient safety continues to expand.
• GMP status: The EU already ties GMP to ISO 22716 as an established requirement. In the US, MoCRA has directed the FDA to issue GMP regulations for cosmetics, but as of early 2026 those final rules have not yet been published.

Common Myths About Cross-Border Compliance

"If my contract manufacturer is GMP-certified, I'm covered in both markets." GMP certification supports quality and consistency, but it doesn't replace facility registration, product listing, PIF preparation, or CPNP notification. Each is a separate legal obligation.

"My US formulation will work fine in the EU if I just translate the label." Ingredient restrictions differ between the two systems. A formulation compliant in the US can contain a substance restricted or banned under an EU Annex.

"Once I've registered, I'm done." Both systems expect ongoing maintenance — biennial facility renewal and annual product listing updates under MoCRA, and PIF updates plus Annex monitoring under the EU Regulation.

Practical Tips for Brands Operating in Both Markets

• Map your product's ingredient list against both current MoCRA guidance and the EU's CosIng database before finalizing a formulation meant for both markets.
• Confirm your contract manufacturer's facility registration status and ask when their next MoCRA renewal is due.
• If selling in the EU, identify your Responsible Person early. This has to be an EU-established entity, and the role can't be left unassigned.
• Build a documentation calendar that tracks MoCRA's biennial facility renewal, annual product listing updates, and the EU's ongoing Annex changes.
• Treat GMP compliance, whether under ISO 22716 or in anticipation of finalized US cosmetic GMP rules, as an operational baseline rather than a one-off certification.

Frequently Asked Questions

Do I need separate Responsible Persons for the US and EU?
Yes. MoCRA's Responsible Person obligations apply to US market distribution, while the EU requires a separately designated Responsible Person established within the EU. The two roles are not interchangeable.

Is EU Annex compliance a one-time check?
No. The EU Annexes are updated several times a year, so ingredient compliance needs to be reviewed on an ongoing basis, not just at product launch.

Has MoCRA finalized its GMP requirements yet?
As of early 2026, the FDA has not issued final GMP regulations under MoCRA, though guidance and enforcement expectations continue to develop. Brands should stay current with FDA updates.

Can one formulation satisfy both regulatory systems?
It's possible, but it requires checking the formulation against both the FDA's ingredient guidance and the EU's Annexes, since restricted substances differ between the two frameworks.

Conclusion

MoCRA and the EU Cosmetics Regulation are both designed to protect consumers, but they get there through different documentation structures, timelines, and points of accountability. For brands operating internationally, the practical takeaway isn't which system is stricter — it's that neither can be treated as a rubber stamp for the other. Formulation, labeling, and safety documentation need to be reviewed against each market's specific requirements.

Navigating both frameworks while managing product development, packaging, and manufacturing can be a lot to coordinate on your own. Acticon Life Sciences supports brands with formulation development and manufacturing that keeps regulatory considerations in view from the early stages of product development, so compliance isn't an afterthought.